Pharmacogenetics of Allelic Variants of CYP2C9 and Clinical Implications among Mexican Patients with Diabetes Mellitus Type 2 Undergoing Treatment with Glibenclamide and Metformin | Chapter 7 | Current Overview on Pharmaceutical Science Vol. 7

 Diabetes  Mellitus Type 2 (DMT2) is a important public health concern in Mexico as well as everywhere.  The majority of Mexican cases with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed sulphonylureas (SUs), that are metabolized by cytochrome P450 2C9. The polymorphisms of CYP2C9 are thought to be being the reason for the extensive variability about SU responses. The current member aims todescribe CYP2C9 polymorphisms (*2, *3 and IVS8-109T) within a sample of Mexican patients accompanying DMT2, while suggesting the potential clinical implications in conditions of glibenclamide response instability. The study included 248 patients accompanying DMT2 who initially agreed to be studied, those contained in the study were treated accompanying glibenclamide (n=11), glibenclamide combined with metformin (n=112) or metformin (n=76), and were afterward genotyped using a reverse transcription all-inclusive polymerase chain reaction (PCR), endpoint allelic bias and PCR amplifying enzymatic restriction fragment long variety. Glibenclamide significantly reduced the pre?prandial sweet liquid (P<0.01) and the percentage of glycated red body fluid (%HbA1c; P<0.01) for IVS8-109A>T compared with linked glibenclamide and metformin treatment. Concerning the various situations with respect to the different genotypes, the percentages acquired were as follows: Glibenclamide A/A, HbA1c<6.5=33.3%; glibenclamide + metformin A/A, HbA1c<6.5=24.6%; gliben-clamide A/T, HbA1c<6.5=33.3%; glibenclamide + metformin A/T, HbA1c<6.5=25%; glibenclamide T/T, HbA1c<6.5=100%; and glibenclamide + metformin T/T, HbA1c<6.5=12.5%. Overall, these judgments show that, while genetically customised prescriptions remain a good goal for increasing healing success, neither allelic modifications nor dosages evidenced a strong equating with biomarker levels within the intentional population; thus, more exact experimental and practical investigations are needed.

Author(s) Details:

Patricia Cuautle Rodríguez,
Department of Pharmacology, School of Medicine, National University of Mexico, Mexico City, Mexico.

Nidia Samara Rodríguez-Rivera,
Departamento de Farmacología, Facultad de Medicina, UNAM, Mexico City, Mexico.

Fernando de Andrés Segura,
Department of Analytical Chemistry and Food Technology, Faculty of Pharmacy, University of Castilla-La Mancha, Albacete, Spain.

Adrián LLerena,
Institute of Biosanitary Research of Extremadura and of the Clinical Research Center of the University Hospital of Badajoz, Spain.

Fernando Castillo-Nájera,
Centro de Salud T-III Portales, Servicios de Salud, Gobierno de la Ciudad de México, México.

Juan Molina-Guarneros,
Departamento de Farmacología, Facultad de Medicina, UNAM, Mexico City, Mexico.

Please see the link here: https://stm.bookpi.org/COPS-V7/article/view/9699